Cargando…

ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report

BACKGROUND: Fanconi syndrome and diabetes insipidus are rare adverse effects of ifosfamide. They usually present with high cumulative doses of this medication. They are mainly related to type II proximal renal tubular dysfunction. These complications typically present with severe polydipsia and poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Torres, Guillermo, Concepción-Zavaleta, Marcio Marcio, Ildefonso-Najarro, Sofía, Plasencia-Dueñas, Esteban, Gonzãles-Yovera, Jhean, Alcalde-Loyola, Carlos, Concepción-Urteaga, Luis, Ramos-Yataco, Anthony, Paz-Ibarra, José, Correa, Ricardo, Roseboom, Pela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625386/
http://dx.doi.org/10.1210/jendso/bvac150.1045
_version_ 1784822482588401664
author Ramos-Torres, Guillermo
Concepción-Zavaleta, Marcio Marcio
Ildefonso-Najarro, Sofía
Plasencia-Dueñas, Esteban
Gonzãles-Yovera, Jhean
Alcalde-Loyola, Carlos
Concepción-Urteaga, Luis
Ramos-Yataco, Anthony
Paz-Ibarra, José
Correa, Ricardo
Roseboom, Pela
author_facet Ramos-Torres, Guillermo
Concepción-Zavaleta, Marcio Marcio
Ildefonso-Najarro, Sofía
Plasencia-Dueñas, Esteban
Gonzãles-Yovera, Jhean
Alcalde-Loyola, Carlos
Concepción-Urteaga, Luis
Ramos-Yataco, Anthony
Paz-Ibarra, José
Correa, Ricardo
Roseboom, Pela
author_sort Ramos-Torres, Guillermo
collection PubMed
description BACKGROUND: Fanconi syndrome and diabetes insipidus are rare adverse effects of ifosfamide. They usually present with high cumulative doses of this medication. They are mainly related to type II proximal renal tubular dysfunction. These complications typically present with severe polydipsia and polyuria accompanied by glycosuria, proteinuria, and some electrolyte abnormalities including hypokalemia, hypophosphataemia, and non-anion gap metabolic acidosis. Clinical case: A 15-year-old male with, a diagnosis of metastatic osteoblastic osteosarcoma in the right distal treated with ifosfamide three years prior to this hospitalization, was admitted to the emergency department complaining of 3 episodes of vomiting, 6 days history of increase volume of the right lower limb and fever. On admission, blood pressure of 80/50 mm Hg, heart rate of 110 beats / minute, respiratory rate of 30 breaths / minute, axillary temperature of 38.3 ° C. It was evident phlogosis at level of the proximal third of the right lower limb. CBC revealed pancytopenia (WBC 5 x10 9 L, Hb 6.8 g/dL, platelets 25×10 3 /mm 3) and ABG and CMP were compatible with mild metabolic acidosis normal AG (pH 7.285, K 1.9 meq / L, Na 156 meq / L, lactate: 0.9 meq / L, HCO3: 17 meq / L). A diagnosis of sepsis was made and the patient was started on meropenem 2g IV every 8 hours, vancomycin 1 g IV every 12 hours, filgastrim 120 ug/daily and one unit of packed RBC. Patient improved after 5 days over the course of his hospitalization. However, on the 18 th day after his hospital admission, he developed a new episode of polyuria, associated with hypocalcemia (7 mg/dL), hypokalemia (2 mEq/L), hypomagnesemia (0.95 mg/dL), hypophosphatemia (0.9 mg/dL) and metabolic acidosis (pH 7.2, bicarbonate 15 mEq/L). Urine analysis revealed glucosuria and proteinuria. Desmopressin test did not showed increase urinary osmolarity thus nephrogenic diabetes insipidus and Fanconi syndrome were diagnosed due to the multiple laboratory abnormalities and sign/symptoms. Patient received electrolyte replacement and ifosfamide was stopped from his chemotherapy regimen. After this, patient recovers and he was discharge at 25 th day of his admission. CONCLUSION: : Ifosfamide causes tubular cell dysfunction leading to both nephrogenic diabetes insipidus and Fanconi syndrome. These complications might event present several years after receiving this chemotherapeutic agent. Full electrolyte repletion and hydration are the gold standard for management The present case report emphasizes the importance of the prevention of nephrotoxicity associated with ifosfamide, since its presentation could increase poor outcomes in patients receiving chemotherapy regimens that include ifosfamide. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96253862022-11-14 ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report Ramos-Torres, Guillermo Concepción-Zavaleta, Marcio Marcio Ildefonso-Najarro, Sofía Plasencia-Dueñas, Esteban Gonzãles-Yovera, Jhean Alcalde-Loyola, Carlos Concepción-Urteaga, Luis Ramos-Yataco, Anthony Paz-Ibarra, José Correa, Ricardo Roseboom, Pela J Endocr Soc Neuroendocrinology and Pituitary BACKGROUND: Fanconi syndrome and diabetes insipidus are rare adverse effects of ifosfamide. They usually present with high cumulative doses of this medication. They are mainly related to type II proximal renal tubular dysfunction. These complications typically present with severe polydipsia and polyuria accompanied by glycosuria, proteinuria, and some electrolyte abnormalities including hypokalemia, hypophosphataemia, and non-anion gap metabolic acidosis. Clinical case: A 15-year-old male with, a diagnosis of metastatic osteoblastic osteosarcoma in the right distal treated with ifosfamide three years prior to this hospitalization, was admitted to the emergency department complaining of 3 episodes of vomiting, 6 days history of increase volume of the right lower limb and fever. On admission, blood pressure of 80/50 mm Hg, heart rate of 110 beats / minute, respiratory rate of 30 breaths / minute, axillary temperature of 38.3 ° C. It was evident phlogosis at level of the proximal third of the right lower limb. CBC revealed pancytopenia (WBC 5 x10 9 L, Hb 6.8 g/dL, platelets 25×10 3 /mm 3) and ABG and CMP were compatible with mild metabolic acidosis normal AG (pH 7.285, K 1.9 meq / L, Na 156 meq / L, lactate: 0.9 meq / L, HCO3: 17 meq / L). A diagnosis of sepsis was made and the patient was started on meropenem 2g IV every 8 hours, vancomycin 1 g IV every 12 hours, filgastrim 120 ug/daily and one unit of packed RBC. Patient improved after 5 days over the course of his hospitalization. However, on the 18 th day after his hospital admission, he developed a new episode of polyuria, associated with hypocalcemia (7 mg/dL), hypokalemia (2 mEq/L), hypomagnesemia (0.95 mg/dL), hypophosphatemia (0.9 mg/dL) and metabolic acidosis (pH 7.2, bicarbonate 15 mEq/L). Urine analysis revealed glucosuria and proteinuria. Desmopressin test did not showed increase urinary osmolarity thus nephrogenic diabetes insipidus and Fanconi syndrome were diagnosed due to the multiple laboratory abnormalities and sign/symptoms. Patient received electrolyte replacement and ifosfamide was stopped from his chemotherapy regimen. After this, patient recovers and he was discharge at 25 th day of his admission. CONCLUSION: : Ifosfamide causes tubular cell dysfunction leading to both nephrogenic diabetes insipidus and Fanconi syndrome. These complications might event present several years after receiving this chemotherapeutic agent. Full electrolyte repletion and hydration are the gold standard for management The present case report emphasizes the importance of the prevention of nephrotoxicity associated with ifosfamide, since its presentation could increase poor outcomes in patients receiving chemotherapy regimens that include ifosfamide. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625386/ http://dx.doi.org/10.1210/jendso/bvac150.1045 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Ramos-Torres, Guillermo
Concepción-Zavaleta, Marcio Marcio
Ildefonso-Najarro, Sofía
Plasencia-Dueñas, Esteban
Gonzãles-Yovera, Jhean
Alcalde-Loyola, Carlos
Concepción-Urteaga, Luis
Ramos-Yataco, Anthony
Paz-Ibarra, José
Correa, Ricardo
Roseboom, Pela
ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title_full ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title_fullStr ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title_full_unstemmed ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title_short ODP336 Nephrogenic Diabetes Insipidus and Fanconi Syndrome Induced by Ifosfamide in a Patient with Femur Osteosarcoma. A Case Report
title_sort odp336 nephrogenic diabetes insipidus and fanconi syndrome induced by ifosfamide in a patient with femur osteosarcoma. a case report
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625386/
http://dx.doi.org/10.1210/jendso/bvac150.1045
work_keys_str_mv AT ramostorresguillermo odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT concepcionzavaletamarciomarcio odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT ildefonsonajarrosofia odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT plasenciaduenasesteban odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT gonzalesyoverajhean odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT alcaldeloyolacarlos odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT concepcionurteagaluis odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT ramosyatacoanthony odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT pazibarrajose odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT correaricardo odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport
AT roseboompela odp336nephrogenicdiabetesinsipidusandfanconisyndromeinducedbyifosfamideinapatientwithfemurosteosarcomaacasereport